Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 496

1.

Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.

Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J.

Am J Kidney Dis. 2007 Mar;49(3):373-82.

PMID:
17336698
2.

Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency.

Tonelli M, Moyé L, Sacks FM, Kiberd B, Curhan G; Cholesterol and Recurrent Events (CARE) Trial Investigators..

Ann Intern Med. 2003 Jan 21;138(2):98-104.

PMID:
12529091
3.

Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

Miettinen TA, Pyörälä K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, Berg K, Pedersen T, Kjekshus J.

Circulation. 1997 Dec 16;96(12):4211-8.

4.

Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).

Tikkanen MJ, Holme I, Cater NB, Szarek M, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR; Incremental DEcrease through Aggressive Lipid Lowering Investigators..

Am J Cardiol. 2009 Mar 1;103(5):577-82. doi: 10.1016/j.amjcard.2008.10.029.

PMID:
19231315
5.

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

Pyŏrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G.

Diabetes Care. 1997 Apr;20(4):614-20. Erratum in: Diabetes Care 1997 Jun;20(6):1048.

PMID:
9096989
6.
7.

Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).

Kjekshus J, Pedersen TR.

Am J Cardiol. 1995 Sep 28;76(9):64C-68C.

PMID:
7572690
8.

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering.

Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyörälä K, Wedel H.

Am J Cardiol. 2000 Aug 1;86(3):257-62.

PMID:
10922429
9.

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K.

Arch Intern Med. 1999 Dec 13-27;159(22):2661-7.

PMID:
10597756
10.

Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.

Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP; ALLIANCE Investigators..

Am J Kidney Dis. 2009 May;53(5):741-50. doi: 10.1053/j.ajkd.2008.11.025.

PMID:
19216014
11.

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.

Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators..

J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072.

12.

Coronary artery disease: the Scandinavian Simvastatin Survival Study experience.

Pedersen TR.

Am J Cardiol. 1998 Nov 26;82(10B):53T-56T.

PMID:
9860376
13.
14.

Primary cardiovascular events and serum lipid levels in elderly Japanese with hypercholesterolemia undergoing 6-year simvastatin treatment: a subanalysis of the Japan lipid intervention trial.

Horiuchi H, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H; J-LIT Study Group..

J Am Geriatr Soc. 2004 Dec;52(12):1981-7.

PMID:
15571531
15.

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators..

N Engl J Med. 2008 Sep 25;359(13):1343-56. doi: 10.1056/NEJMoa0804602.

16.

Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).

Pyörälä K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, Mitchel YB, Pedersen TR, Kjekshus J; Scandinavian Simvastatin Survival Study (4S)..

Diabetes Care. 2004 Jul;27(7):1735-40.

PMID:
15220255
17.

The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials.

Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J.

Int J Cardiol. 2007 Apr 12;117(1):64-74. Review.

PMID:
16889855
18.

Reduction of myocardial ischemia with simvastatin in addition to conventional treatment in patients with chronic coronary artery disease.

Verri V, Cunha AB, Tessarolo LE, Carneiro RC, Romêo Filho LJ.

Rev Port Cardiol. 2004 Sep;23(9):1089-105. English, Portuguese.

19.

Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.

Sever PS, Poulter NR, Dahlof B, Wedel H; ASCOT Investigators..

J Hypertens. 2009 May;27(5):947-54. doi: 10.1097/HJH.0b013e328326cb1a.

PMID:
19318984
Items per page

Supplemental Content

Support Center